Primatene Mist CRL Underscores Challenges For OTC Asthma Treatments
This article was originally published in The Pink Sheet
Second FDA complete response letter for a reformulated Primatene Mist likely pushes back by another 18 months Amphastar's potential relaunch of the OTC product after satisfying the US agency's concerns about consumers correcting using the product without a doctor’s intervention.
You may also be interested in...
US FDA Connects Dots For Drug Manufacturers’ Responses To CRLs With Draft Guidance
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.
Keeping Track: CDER 2016 Novel Approvals Hold At 22 As US FDA Declines Cempra's Solithera
The latest drug development news and highlights from our FDA Performance Tracker.
Dry Powder Blows Dr. Natural OTC Epinephrine Inhaler Out Of Compliance
Dr. Natural Healing markets its Prime Asthma Relief Start Kit with an epinephrine delivery form – a capsule added to a dry powder inhaler – not approved under the OTC bronchodilator monograph, FDA says in a warning letter, its latest enforcement against OTC asthma inhalers it considers noncompliant.